Signature based on metabolic‐related gene pairs can predict overall survival of osteosarcoma patients

Abstract

Background Osteosarcoma is a tumour of malignant origin in children and adolescents. Recent progression indicates that it is necessary to develop new therapies to improve the patient's prognosis rather than strengthen anti‐tumour chemotherapy. Researchers recently realised that cancer is a kind of disease with a metabolic disorder, and metabolic reprogramming is becoming a new cancer hallmark. Hence, our study's primary purpose is to explore the value of genes related to osteosarcoma metabolism. Methods From public databases, three osteosarcoma datasets with adequate clinical information were obtained. Besides, the IMvigor dataset through the ‘IMvigor’ package as a supplement was downloaded, the metabolic‐related genes were identified, and these genes were used to construct the metabolic‐related gene pairs (MRGP). Based on the prognosis‐related MRGP, two molecular subtypes were identified. There are significant differences in the metabolic characteristics between the two molecular subtypes. Subsequently, the MRGP signature is constructed using the least absolute shrinkage and selection operator regression method. Finally, use SubMap analysis to evaluate the response of patients in the MRPG signature group to immunotherapy. Results The MRGP signature can reliably predict overall survival in patients with osteosarcoma. The MRGP signature is also associated with osteosarcoma patients’ metastatic status and can be used for subsequent risk classification of metastatic patients. The immunotherapy is more likely to benefit the patients in the MRGP low‐risk group. Conclusion Metabolic‐related gene pairs signature can assess the prognosis of patients with osteosarcoma.

Immune‐related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia

“…Our study has many highlights. Several researches previously have proposed certain risk signatures based on various characteristics, in hopes of stratifying the prognosis of cancer patients 53,54 . Zheng et al have identified a signature of seven‐lncRNA to predict the OS of patients with AML 6 .…”

Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients

“…Recently, several novel assays such as lncRNAs have been developed. However, these methods are still some ways from clinical applications due to their high cost, difficulty in being obtained, and unified detection methods (42)(43)(44)(45). Meanwhile, the predictive effect of hematological markers has been widely explored.…”

Global Characterization of Metabolic Genes Regulating Survival and Immune Infiltration in Osteosarcoma

“…Osteosarcoma is a rare type of cancer that affects the individuals of all ages including children ( Yang et al, 2021 ). However, because of the advancements in chemotherapy, precise radiotherapy, and immunotherapy, the overall 5-year overall survival (OS) rate of patients has substantially increased to 70% ( Li et al, 2021 ). It is noteworthy that only 15% to 20% of the patients were usually diagnosed with metastases, and the OS of these patients was reported to be extremely poor ( Durnali et al, 2013 ; Zhang et al, 2019 ).…”